Eventide Asset Management, LLC / NBIX
Eventide Asset Management, LLC’s Neurocrine Biosciences Inc Position
Does Eventide Asset Management, LLC own Neurocrine Biosciences Inc (NBIX)? Not currently — the last reported position was 135.0K shares worth $15M in Q3 2023; the fund’s latest 13F (Q1 2026) no longer reports it.
Position Value
$15M
Q3 2023
Shares
135.0K
% of Portfolio
+0.27%
Quarters Held
20
position exited
Position History NBIX
Reported value by quarter
| Quarter | Shares | Value | % of Portfolio |
|---|---|---|---|
| Q3 2023 | 135.0K | $15M | +0.27% |
| Q2 2023 | 135.0K | $13M | +0.22% |
| Q1 2023 | 135.0K | $14M | +0.25% |
| Q4 2022 | 135.0K | $16M | +0.32% |
| Q3 2022 | 235.0K | $25M | +0.49% |
| Q2 2022 | 235.0K | $23M | +0.49% |
| Q1 2022 | 235.0K | $22M | +0.35% |
| Q4 2021 | 235.0K | $20M | +0.26% |
| Q3 2021 | 235.0K | $23M | +0.30% |
| Q2 2021 | 235.0K | $23M | +0.31% |
| Q1 2021 | 474.0K | $46M | +0.68% |
| Q4 2020 | 353.0K | $34M | +0.52% |
| Q3 2020 | 360.2K | $35M | +0.68% |
| Q2 2020 | 357.8K | $44M | +0.95% |
| Q1 2020 | 353.0K | $31M | +0.99% |
| Q4 2019 | 353.0K | $38M | +1.07% |
| Q3 2019 | 353.0K | $32M | +1.05% |
| Q2 2019 | 353.0K | $30M | +0.91% |
| Q1 2019 | 270.0K | $24M | +0.82% |
| Q4 2018 | 156.0K | $11M | +0.49% |
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Eventide Asset Management, LLC’s full portfolio or all institutional holders of NBIX.